Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · IEX Real-Time Price · USD
1.400
-0.020 (-1.41%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Spero Therapeutics stock has a target of 7.00, which predicts an increase of 400.00% from the current stock price of 1.40.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2024.
Analyst Ratings
The average analyst rating for SPRO stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +400.00% | May 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +400.00% | Mar 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +400.00% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +400.00% | Sep 5, 2023 |
Financial Forecast
Revenue This Year
27.94M
from 103.78M
Decreased by -73.08%
Revenue Next Year
35.12M
from 27.94M
Increased by 25.72%
EPS This Year
-1.29
from 0.43
EPS Next Year
-1.22
from -1.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 41.1M | 58.3M | 90.5M | 103.6M | 138.2M |
| Avg | 27.9M | 35.1M | 57.4M | 82.3M | 134.2M |
| Low | 8.9M | n/a | 25.8M | 61.3M | 129.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -60.4% | 108.6% | 157.7% | 80.6% | 68.0% |
| Avg | -73.1% | 25.7% | 63.4% | 43.4% | 63.2% |
| Low | -91.4% | - | -26.6% | 6.9% | 56.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.06 | -0.91 | -0.09 | 0.24 | 0.58 |
| Avg | -1.29 | -1.22 | -0.66 | -0.21 | 0.56 |
| Low | -1.57 | -1.67 | -1.18 | -0.64 | 0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.